Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Thrombolytic Therapy May Reduce Amputation in Frostbite

By HospiMedica staff writers
Posted on 05 Jul 2007
A new study has found the thrombolytic therapy with tissue plasminogen activator (tPA) might reduce the need for amputation in frostbite injury. More...


Investigators from the University of Utah (Salt Lake City, USA) conducted a retrospective review of clinical outcomes and resource use considered for patients admitted to the burn unit of a tertiary academic referral center. From 2001 to 2006, patients who were admitted within 48 hours of severe frostbite injury underwent digital angiography and treatment with intra-arterial tPA if there was abnormal perfusion. These patients were compared with those treated from 1995 to 2006, who did not receive tPA. Primary end points included number and type of surgery, amputations of digits (fingers or toes), and more proximal amputations (ray, transmetatarsal, or below-knee).

Of 32 patients with digital involvement (hands, 19%; feet, 62%; both, 19%), seven received tPA, six of whom received it within 24 hours of injury. Digital amputation occurred in 41% of patients who did not receive tPA. Of those who received tPA within 24 hours of injury, only 10% underwent amputation. The results of the study were published in the June 2007 issue of the Archives of Surgery.

"Based on the dramatic improvements in perfusion and reduction in rates of amputations when tPA was administered within 24 hours of frostbite injury, we anticipate the continued use of tPA in patients who are admitted to our institution with acute frostbite,” concluded said lead author Kevin J. Bruen, M.D., and colleagues. "Additional studies are warranted to confirm our findings and to determine the best methods of assessing tissue damage and administering thrombolytics in terms of timing, duration, and route.”

Limitations to the study include small sample size, retrospective review, inability to compare equal groups for severity, lack of historic control group with angiographic evidence of the absence of blood flow, lack of data on functional outcomes, and inability to disprove that patients who received tPA might have improved on their own without thrombolytic therapy.


Related Links:
University of Utah

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.